Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Melinta Therapeutics Inc.

Latest From Melinta Therapeutics Inc.

AMR Crisis Experts See Hopeful Signs For 2020

2020 could be a watershed year in tackling AMR, but success needs market reforms that ensure new antibiotics get to market and prevent innovators going bust, experts tell Scrip. 

Policy Research & Development

Antabio CEO Says M&A Is His ‘Exit Strategy’

Antibiotics specialist Antabio aims to get enough funding to advance its pipeline far enough to become a takeover target.     

Companies Strategy

Finance Watch: Intrexon Reorganizes, Raises Cash And Becomes Precigen

The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.

Financing Deals

It Has Been A Long Farewell To The Medicines Company

The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.

Companies Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Rib-X Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Melinta Therapeutics Inc.
  • Senior Management
  • Peter Milligan, CFO
    Sue Cammarata, MD, CMO
    Ryan Lococo, VP, Corp. Dev. & Strategy & CBO
    Erin Duffy, PhD, CSO
  • Contact Info
  • Melinta Therapeutics Inc.
    Phone: (203) 624-5606
    300 George St., Ste. 301
    New Haven, CT 06511-6663
    USA
UsernamePublicRestriction

Register